Tout médicament administré par la voie orale doit être absorbé sans être métabolisé par l’intestin et le foie pour atteindre la circulation systémique. Malgré son impact majeur sur l’effet de premier passage de plusieurs médicaments, le métabolisme intestinal est souvent négligé comparativement au métabolisme hépatique. L’objectif de ces travaux de maîtrise est donc d’utiliser, caractériser et développer différents outils in vitro et in vivo pour mieux comprendre et prédire l’impact du métabolisme intestinal sur l’effet de premier passage des médicaments comparé au métabolisme hépatique. Pour se faire, différents substrats d’enzymes du métabolisme ont été incubés dans des microsomes intestinaux et hépatiques et des différences entre la vitesse de métabolisme et les métabolites produits ont été démontrés. Afin de mieux comprendre l’impact de ces différences in vivo, des études mécanistiques chez des animaux canulés et traités avec des inhibiteurs enzymatiques ont été conduites avec le substrat métoprolol. Ces études ont démontré l’impact du métabolisme intestinal sur le premier passage du métoprolol. De plus, elles ont révélé l’effet sur la vidange gastrique du 1-aminobenzotriazole, un inhibiteur des cytochromes p450, évitant ainsi une mauvaise utilisation de cet outil dans le futur. Ces travaux de maîtrise ont permis d’améliorer les connaissances des différents outils in vitro et in vivo pour étudier le métabolisme intestinal tout en permettant de mieux comprendre les différences entre le rôle de l’intestin et du foie sur l’effet de premier passage. / To reach the systemic circulation, orally administered drugs have to be absorbed and not metabolized by the intestine and the liver. Even though it has a major impact on the first pass effect of many xenobiotics, the intestinal metabolism is often neglect compare to the hepatic metabolism. The objective of this work is to use, characterize and develop multiple in vitro and in vivo tools to better understand and predict the impact of intestinal metabolism on the first pass effect of xenobiotics compared to the liver. To do so, multiple substrates of metabolic enzymes were incubated in intestinal and hepatic microsomes and differences between the rate of metabolism and the production of metabolites were demonstrated. To better understand the impact of these differences in vivo, mechanistic studies were undergone in rats cannulated or treated with enzymatic inhibitors with the substrate metoprolol. These studies demonstrated the impact of intestinal metabolism on the first pass of metoprolol. Moreover, they exposed the effect on gastric emptying of 1-aminobenzotriazole, a cytochrome p450 inhibitor, avoiding its wrong utilisation in future studies. This work helped increase the knowledge about the different in vitro and in vivo tools to study intestinal metabolism and to better understand the differences between the role of the intestine and the liver on the first pass effect.

7 Abstract Neuroblastoma is the most common extracranial solid tumor of childhood. Despite advances in cancer diagnosis and therapy, the treatment of some forms of neuroblastoma is still complicated. One of the major complications of the chemotherapy is a developed drug resistance. This master thesis deals with the effect of cytostatics on protein and gene expression of selected proteins, which may contribute to chemoresistance of the human neuroblastoma cell line UKF-NB-4. The sensitive line UKF-NB-4 and the resistant line UKF-NB-4CDDP , UKF-NB-4DOXO and UKF-NB-4ELLI were exposed to cisplatin, doxorubicin, ellipticine for 24, 48 and 72 hours. The Western blot analysis showed that cytostatic agents cisplatin, doxorubicin or ellipticine added to the sensitive neuroblastoma cell line UKF-NB-4 in amounts which are added to resistant neuroblastoma cell lines in order to maintain resistance induced expression of p53 and reduced expression of retinoblastoma protein pRb after 72 hours of cultivation. Differences in the expression of RAS protein, cytochrome P450 1A1, 3A4 and cytochrome b5 has not been shown. Changes in the expression of the studied proteins in resistant lines UKF-NB-4CDDP , UKF-NB-4DOXO and UKF-NB-4ELLI cultured with and without cytostatic agents were not detected by the Western blot analysis....

Aristolochic acids (AA) are carcinogenic and nephrotoxic alkaloids from Aristolochia species. Aristolochic acid I (AAI), the major component of AA, causes the development of Aristolochic acid nephropathy (AAN) and Balkan endemic nephropathy (BEN). These two diseases cause total renal failure and urothelial malignancies. The fact that these diseases have not been developed in all persons, who have been exposed to their action, might be causd by different activities and protein levels of the enzymes metabolizing AAI. Thus, the identification of enzymes involved in the metabolism, and detailed knowledge of their expression and catalytic specifities is a major importance. Aristolochic acid I (AAI) can be metabolized by several types of reactions. Like most nitroaromatics, the main activation pathway of AAI is reduction of its nitro group to form a cyclic acylnitrenium ion, which can bind to the purine bases, thereby forming AAI-DNA adducts. The detoxication pathway of AAI is its oxidative demethylation by cytochromes P450 forming detoxication metabolite 8-hydroxyaristolochic acid Ia (AAIa). In the present thesis, using rat and human enzymes and as well as several mice models, the metabolism of AAI in vitro and in vivo was investigated. The first model has deleted gene for NADPH:cytochrome P450...

13 Abstract An environmental pollutant and a human carcinogen benzo[a]pyrene (BaP) is after its activation with cytochrome P450 (CYP) able to covalently bind to DNA. In the thesis, one of the target was to investigate an influence of individual components of mixed function monooxygenase (MFO) system on metabolism of benzo[a]pyrene and generation of adducts of activated BaP with DNA. The study was particularly focused to increase our knowledge on the effect of cyt b5 on metabolism of BaP by cytochrome P450 1A1 (CYP1A1) and its potential to serve as a donor of electrons during the reaction cycle of this cytochrome P450. The effect of cyt b5 on generation of BaP metabolites and adducts of BaP with DNA was investigated. In addition the effect of two different expression systems for cytochrome P450 1A1 (prokaryotic and eukaryotic) was also studied. The influence of cyt b5 on oxidation another xenobiotic compound, a plant alkaloid ellipticine that exhibit antitumor activities, was also investigated. Its pharmacological efficiency, as well as side effects depends on its metabolic activation by cytochrome P450. CYP3A4 is very important for ellipticine activation and therefore this enzyme was used in our experiments. Furthermore, a suitability of rat as a model organism mimicking the metabolic fate of BaP...

6 Abstract Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole), an alkaloid isolated from Apocynaceae plants, exhibits significant antitumor and HIV activity. This antitumor agent binds to DNA and forms covalent DNA adducts. Enzymes, which are involved in its enzymatic activation, are cytochromes P450 (CYP) and peroxidases. To elucidate the effect of ellipticine on the expression and enzymatic activity of the individual components of the microsomal mixed function oxidase system in different tissues, we used rat model. Simultaneously, the effect of ellipticine and its cytotoxicity on different tumor cell lines was also investigated. Another part of the presented work was targeted on preparation of anti-peptide antibody against orphan cytochrome P450 2S1, which is highly expressed in many human tumours of the epithelial origin, for its detection in these tissues. For better understanding how CYP2S1 can contribute to the metabolism of xenobiotics, the protein was prepared by heterologous expression in E. coli. Furher, its role in metabolism of an antitumor drug ellipticine, a carcinogenic environmental pollutant benzo[a]pyrene (BaP) and its derivate BaP-7,8-dihydrodiol was examined. Utilizing a mouse model, the impact of pulmonary inflammation on the metabolism of an environmental carcinogen was...

Die Umwandlung in wasserlösliche Verbindungen, die renal ausgeschieden werden können, ist ein grundlegendes Prinzip im Abbau von Fremdstoffen. Hierbei unterscheidet man Phase-I- und Phase-II-Reaktionen. Die Aktivität vieler Phase-I- und Phase-II-Enzyme ist genetisch beeinflusst und kann starke interindividuelle Unterschiede im Metabolismus von Fremdstoffen verursachen und dadurch das Krebsrisiko und das Risiko für Arzneimittelnebenwirkungen beeinflussen. Die Häufigkeitsverteilungen der Allele der Gene, die Phase-I- und Phase-II-Enzyme kodieren, zeigen eine große interethnische Varianz. Die Polymorphismen dieser Enzyme wurden bisher jedoch noch nicht in der größten slawischen Volksgruppe, der russischen, untersucht. An der vorliegenden Studie nahm eine Gruppe von 325 Personen russischer Abstammung teil - gesunde Probanden bzw. Patienten, die nicht an einer malignen Erkrankung litten. Die Polymorphismen von zwei Enzymen der Phase I, CYP1A1 und CYP2D6, und von einem Enzym der Phase II, NAT2, wurden mittels PCR-RFLP-Genotypisierung und Real-time-PCR-Verfahren komplett untersucht. Die Häufigkeit der CYP1A1 Allele mit hoher Aktivität, CYP1A1*2A und CYP1A1*2B, betrug 4,6% (3,1%-6,5%) bzw. 5,1% (3,5%-7,1%). Die Häufigkeiten der genetischen Varianten von CYP1A1 waren: m1 (3801T>C) - 9,8% (95% Vertrauensbereich, 7,7%-12,4%), m2 (2455A>G) - 5,0% (95% VB, 3,5%-7,1%), m4 (2453C>A) - 2,5% (1,4%-4,0%), m5 (-4335G>A) - 25,8% (22,5%-29,4%), m6 (-3219C>T) - 6,0% (4,3%-8,1%), und m7 (-3229G>A) - 2,9% (1,8%-4,5%). Die Mutation m3, die bisher nur bei Afrikaner gefunden wurde, konnten wir nicht nachweisen. 5,9% (3,5%-9,2%) aller Probanden waren CYP2D6 Langsam-Metabolisierer und 3,4% (1,7%-6,3%) wurden als Ultraschnell-Metabolisierer identifiziert (CYP2D6*1x1/*1). Bei der Genotypisierung von acht verschiedenen Punktmutationen im NAT2-Gen ergab sich für 59,7% (54,1%-65,1%) der Studienteilnehmer ein Genotyp, der mit einer Langsam-Acetylierer-Status einhergeht. 34,7% (29,6%-40,2%) der Probanden hatten ein und 5,6% (3,3%-8,6%) zwei für die Schnellacetylierung kodierende Allele. Die Allelverteilung der für die wichtigsten Enzyme im Arzneimittelstoffwechsel kodierenden Gene ist bei Russen ähnlich wie bei anderen Kaukasiern. Es kann deshalb erwartet werden, dass die genetisch-bedingten Unterschiede in der Wirksamkeit und im Auftreten von Arzneimittelnebenwirkungen in der russischen Bevölkerung vergleichbar sind mit denen in anderen europäischen Populationen. / The basic principle of drug and xenobiotic metabolism in the body is to make them more water soluble and thus more readily excreted in the urine. Genetic polymorphisms of phases I and II xenobiotic transformation reactions are known to contribute considerably to interindividual variations in the metabolism of numerous drugs and xenobiotics and to associate with altered risk of adverse drug reactions and some cancers. The frequency of functionally important mutations and alleles of genes coding for xenobiotic metabolizing enzymes shows a wide ethnic variation. However, little is known of the frequency distribution of the major allelic variants in the Russian population. In this study we investigated 325 individuals of Russian origin, who were healthy volunteers or patients without malignant diseases. Our study included the complete investigation of two enzymes of phase I, CYP1A1 and CYP2D6, and one phase II enzyme, NAT2, using PCR-RFLP genotyping and LightCycler method. The frequencies of the CYP1A1 high-activity alleles, CYP1A1*2A and CYP1A1*2B, were 4.6% (3.1%-6.5%) and 5.1% (3.5%-7.1%), respectively. The mutations m1 (3801T>C), m2 (2455A>G), m4 (2453C>A), m5 (-4335G>A), m6 (-3219C>T), and m7 (-3229G>A) of CYP1A1 occurred in 9.8% (95% confidence interval, 7.7%-12.4%), 5.0% (95% C. I., 3.5%-7.1%), 2.5% (1.4%-4.0%), 25.8% (22.5%-29.4%), 6.0% (4.3%-8.1%), and 2.9% (1.8%-4.5%) of alleles, respectively. We did not find the m3 mutation, which has only been detected in Africans up to now. 5.9% (3.5%-9.2%) of all subjects were CYP2D6 poor metabolizers, whereas 3.4% (1.7%-6.3%) were identified as ultra-rapid metabolizers (CYP2D6*1x1/*1). Genotyping eight different single nucleotide polymorphisms in the NAT2 gene provided a genotype associated with slow acetylation in 59.7% (54.1%-65.1%) of individuals, 34.7% (29.6%-40.2%) of participants carried at least one allele encoding rapid acetylation, and 5.6% (3.3%-8.6%) were homozygous for the rapid-acetylation allele (wild-type allele *4 or mutant allele *12A). The overview of allele distribution of the important drug and xenobiotic metabolizing enzymes among Russians shows that the allele frequency is similar to that of other Caucasians. Therefore it may be expected that drug side effects and efficacy problems due to an individual's genetic background are similar compared to those in other European populations.

Genetische Polymorphismen in den Enzymen CYP2D6, CYP2C19 und CYP2C9 beeinflussen die Pharmakokinetik medizinisch bedeutsamer Arzneimittel wie Antidepressiva, oraler Antidiabetika und nichtsteroidaler Antiphlogistika in erheblichem Ausmaß. In der Zukunft kann die Bestimmung genetischer Varianten bei Patienten zur Verbesserung der Arzneitherapie genutzt werden, jedoch nur dann, wenn klinische Konsequenzen wie konkrete Therapieempfehlungen aus den genetischen Daten abgeleitet werden können. An gesunden Probanden wurde die die Bedeutung der beiden Aminosäurevarianten des Enzyms CYP2C9, Arg144Cys (CYP2C9*2) und Leu359Ile (CYP2C9*3) für die Pharmakokinetik von Tolbutamid, Glibenclamid, Nateglinid, Diclofenac, Ibuprofen, Celecoxib und Fluvastatin untersucht. Die Analyse der pharmakokinetischen Parameter ergab eine erheblich erniedrigte Clearance für diese Substrate bei homozygoten Trägern der Allelvariante CYP2C9*3, wie sie etwa 1% in der Bevölkerung tragen. Um bioäquivalente Konzentrationsverläufe zu erreichen, müssten diese Patienten deutlich niedrigere Dosierungen (unter 50%) der meisten der untersuchten CYP2C9-Substrate erhalten. Hingegen zeigte die CYP2C9*2-Variante nur einen geringen Einfluss auf die Pharmakokinetik der untersuchten Medikamente. Für den Bereich der Therapie mit Antidepressiva und Antipsychotika sollte untersucht werden, inwieweit umfassende pharmakogenetisch begründete Therapieempfehlungen gegeben werden können. Eine systematische Analyse aller bisher publizierten Daten zum Einfluss von Polymorphismen von CYP2D6, CYP2C19 und CYP2C9 ergab, dass für die meisten gängigen Antidepressiva bereits Studien zur Bedeutung von Cytochrom-P450-Polymorphismen durchgeführt wurden. Für die beiden in Deutschland sehr häufig verwendeten Trizyklika Trimipramin und Doxepin dagegen lagen keine ausreichenden Daten vor. Beide Medikamente wurden deshalb bei Probanden getestet, die jeweils Träger eines oder zweier Allele mit defizienter oder herabgesetzter Enzymaktivität von CYP2D6, CYP2C19 oder CYP2C9 waren. Es ergab sich ein deutlicher Einfluss des CYP2D6-Genotyps, ein schwächerer von CYP2C19 und des Genotyps CYP2C9*3/*3. Eine Dosisreduktion für Langsam-Metabolisierer von CYP2D6 und etwas moderater für Langsam-Metabolisierer von CYP2C19, sowie für Träger des Genotyps CYP2C9*3/* erscheint für diese beiden Antidepressiva sinnvoll. Die eigenen Daten und die Daten für andere Antidepressiva aus der Literatur wurden dazu verwendet, eine Methode zur Ableitung von pharmakogenetisch basierten Dosierungsempfehlungen zu entwickeln. Auf dem Prinzip der Bioäquivalenz basierend wurden Dosierungsanpassungen für unterschiedliche Genotypen je nach Unterschieden in der Clearance von Substanzen errechnet. Durch diese Dosierungsanpassungen können zumindest theoretisch die durch herabgesetzte Enzymaktivität verursachten Unterschiede in den Plasmakonzentrationsverläufen von Medikamenten ausgeglichen werden. Dabei wurden aktive an der Arzneimittelwirkung teilhabende Metaboliten mit berücksichtigt. Auf Seiten der Pharmakodynamik wurden die vielen Studien zu genetischen Polymorphismen in Serotonin-, Dopaminrezeptoren und Transportern und auch zu anderen Kandidatengenen für die Antidepressiva-, und Antipsychotikawirkung analysiert. Jedoch lassen sich aus den teilweise geringen Einflüssen einzelner Genotypen auf die Arzneimittelwirkung derzeit noch keine pharmakodynamisch begründeten Therapieempfehlungen ableiten. Zusammenfassend lassen sich also bereits heute pharmakogenetisch basierte Dosierungsempfehlungen für viele Medikamente berechnen. Derartige Empfehlungen müssen prospektiv überprüft, validiert und angepasst werden. Auf Seiten der Zielmoleküle der Arzneimittelwirkung ist eine Ableitung genetisch basierter Therapieempfehlungen schwieriger. Das Ziel, konkrete Therapieempfehlungen aus genetischen Daten abzuleiten, ist eine notwendige Bedingung, um Pharmakogenetik in die klinische Praxis der Arzneitherapie einzuführen. / Genetic polymorphisms of the cytochrome P450 enzymes CYP2D6, CYP2C19 and CYP2C9 largely influence pharmacokinetics of clinically important drugs such as antidepressants, oral antidiabetics and nonsteroidal antiphlogistic drugs. Pharmacogenetic diagnostics is ready to be used for optimization of drug treatment in the future if concise recommendations for clinical decisions can be derived from the genetic data. Panel studies in healthy volunteers served to characterize the impact of the amino acid variants Arg144Cys (CYP2C9*2) and Leu359Ile (CYP2C9*3) in cytochrome P450 2C9 on pharmacokinetics of the oral antidiabetics tolbutamide, glyburide and nateglinide, of the nonsteroidal analgetic drugs diclofenac, ibuprofen, celecoxib, and of fluvastatin. Analysis of pharmacokinetic parameters revealed largely reduced oral clearances in homozygous carriers of the CYP2C9*3 allele for most of the substrates studied. About 1% in the general population are carriers of this genotype and patients should get about 50% lower doses of most of the CYP2C9 substrates in order to achieve similar plasma concentration versus time courses. In contrast, the CYP2C9*2 variant had little influence on pharmacokinetics of the CYP2C9 substrates. For antidepressant and antipsychotic drug therapy, the aim was to derive detailed dose recommendations from the large amount of data existing. Thus, a systematic analysis of all published data on the clinical influence of genetic polymorphisms in CYP2D6, CYP2C19 and CYP2C9 was performed and dose recommendations were given for many antidepressants. For two substances, the tricyclics doxepin and trimipramine, no pharmacogenetic data have been found, and therefore own clinical studies were performed. Healthy volunteers who were heterozygous and homozygous carriers of alleles with deficient activity of CYP2D6, CYP2C19 or CYP2C9 were tested for differences in metabolism and elimination of doxepin and trimipramine and compared to carriers of the wildtype. A significant influence of the CYP2D6 genotype was detected whereas CYP2C19 and the genotype CYP2C9*3/*3 had smaller influences. A significant dose reduction for CYP2D6 poor metabolizers and a smaller reduction for CYP2C19 poor metabolizers would be predicted from these data. According the principles of bioequivalence, calculation methods for pharmacogenetic based dose recommendations from clearance or drug concentration data were developed. Using all published data and the own study results, we developed dose adjustments for each genotype. These dose adjustments would allow to compensate for lower drug clearance caused by genetic variants. Active metabolites which contribute to overall drug effects were considered as well. With regard to target molecules of antidepressant and antipsychotic drug action, many studies have been performed on genetic polymorphisms in serotonin-, and dopamine receptors and in transporter molecules but as well in other candidate genes. However, it is not yet possible to derive therapeutic consequences based on these data. In conclusion, on the pharmacokinetic side of drug action, we are already able to give pharmacogenetic based therapeutic recommendations by adjusting the doses according to genotype. However, the benefit of pharmacogenetic dose adjustments has to be studied prospectively. With regard to the pharmacodynamic side of drug action, the situation is much more complex and we are not yet ready to give pharmacogenetics based therapeutic guidelines. However, this has to be a major goal in order to introduce pharmacogenetic diagnostic into clinical practice.

Die vorliegende Arbeit hatte die Aufgabe, die humane Hepatomzellinie Hep G2 hinsichtlich ihrer Biotransformationskapazität zu charakterisieren, um Aussagen über ihre Eignung als in vitro-Testsystem treffen zu können. Dazu wurden die Aktivitäten und die Induzierbarkeit von unterschiedlichen Cytochrom P450 Isoenzymen (CYP) bestimmt und mit Aktivitäten von isolierten Hepatozyten der Wistarratte verglichen. Als Vertreter der Phase II-Reaktionen wurde die Konjugierung von p-Nitrophenol untersucht. Hep G2-Zellen enthielten detektierbare CYP 1 A1 und 2-Aktivitäten, was mit Hilfe des 7-Ethoxyresorufin- und des 7-Ethoxycoumarin-Assays festgestellt werden konnte. Die Enzymaktivitäten waren durch 3-Methylcholanthren und Phenobarbital induzierbar. Die Umsatzraten waren höher als in Monolayerkulturen von Rattenhepatozyten. Die Umsatzraten der Azoreduktion von 4-(N,N-Dimethylamino)azobenzen waren in Hep G2-Zellen ebenfalls höher als in Hepatozyten der Wistarratte. Hep G2-Zellen zeigten sich hinsichtlich der Demethylierung von Aminophenazon, katalysiert durch CYP 3A1 und 2, und der Konjugierung von p-Nitrophenol den Rattenhepatozyten unterlegen. Die Konjugierung war durch 3-Methylcholanthren und Phenobarbital induzierbar. Des weiteren wurde die Biotransformation von 3 potentiellen Arzneistoffen in Hep G2-Kulturen untersucht. Dabei handelte es sich um AWD 100-041(3-(2-Mercaptoethyl)chinazolin-2, 4(1H,3H)-dion), AR 12463 (5-Piperidino-7-[N-pentyl-N (ß-hydroxyethyl)]amino-s-triazolo(1,5a)-pyrimidin) und dem Lipoxygenaseinhibitor FLM 5011(2-Hydroxy-5-methyllaurophenon -oxim). In allen drei Fällen wurden zwar die gleichen Hauptmetaboliten wie in Rattenhepatozyten gebildet, die Umsatzraten waren aber wesentlich geringer. Um die Toxizität dieser drei Verbindungen und die von Solanum lycopersicon- Mazeraten zu untersuchen, wurde der Proteingehalt und der DNA-Gehalt mit Hilfe von Amidoschwarz bzw. bisBenzimid der Kulturen bestimmt. Membranschäden wurden durch den LDH Cytotoxicity Test von Boehringer Mannheim detektiert. Unter anderem konnte gezeigt werden, daß die Toxizität von FLM 5011 in Hep G2-Zellen auf die Induktion apoptotischer Prozesse zurückzuführen ist, welche durch die sinkende Konzentration von 5(S)-Hydroxyeikosatetraensäure in der Zelle ausgelöst wird. Insgesamt stellen Hep G2-Zellen ein brauchbares in vitro-Modell für Biotransformations- und Zytotoxizitätsuntersuchungen dar. / This investigations had the intention to characterise the capacity of biotransformation of the human hepatoblastoma- derived cell line Hep G2 and to draw conclusions about its suitability as in vitro-model. The enzyme activities and inducabilities of cytochrome P450 isoenzymes (CYP) as phase I reactions were measured and compared with the activity of monolayer primary cultures of rat hepatocytes. As a phase II-reaction the conjugation of p-nitrophenol was examined. Hep G2 contained detectable activities of CYP 1A1 and 2 measured by the 7-ethoxyresorufin assay and the 7-ethoxycoumarin assay and which were inducable by 3-methylcholanthrene and phenobarbitone. The turnover was higher than in rat hepatocytes. Also reductive activities, detected by the azoreduction of 4-(N,N-dimethylamino)- azobenzene, had a higher level than rat hepatocytes. Hep G2 cells were inferior compared to rat hepatocytes concerning the demethylation of aminophenazone catalysed by CYP 3A1 and 2 and the conjugation of p-nitrophenol. The latter was highly inducable by phenobarbitone. The biotransformation of the three active substances AWD 100-041 (3-(2-mercaptoethyl) chinazoline-2,4(1H,3H)-dione), AR 12463(5-piperidino-7-[N- pntyl-N (ß-hydroxyethyl)]amino-s-triazolo[1,5a)-pyrimidin) and the lipoxygenase-inhibitor FLM 5011(2-hydroxy-5- methyllaurophenone-oxim) in Hep G2 cell were also examined. In all cases the major metabolites were the same as in rat hepatocytes but the turnover was much lower than in rat hepatocytes. To study the toxicity of these three compounds and of Solanum lycopersicon mazerates the protein and the DNA content of the Hep G2 cultures were measured with amido black and bisbenzimid respectively. Membrane damages were detected by the LDH Cytotoxicity Test of Boehringer Mannheim. It could be proved that the toxicity of FLM 5011 is due to apoptotic activities aroused by the down regulation of 5-(S)hydroxyeicosatetraenoic acid. Hep G2 cells are a useful model for assessing the metabolism and toxicity of xenobiotics.

A (-)- grandisina (GRA) é um produto natural da classe das lignanas e é encontrada em muitas espécies de plantas das regiões Norte e Nordeste do Brasil. Por apresentar diversas propriedades biológicas, como atividade tripanocida, anti-inflamatória, antinociceptiva, e principalmente atividade antileucêmica e antitumoral contra tumores de Ehrlich, a GRA pode ser considerada um potencial candidato a fármaco. Porém, para que a GRA se torne um fármaco são necessárias diversas etapas de estudos, incluindo estudos pré-clínicos de interações medicamentosas (DDI). As DDI ocorrem principalmente devido a inibições diretas e tempo-dependentes das enzimas do citocromo P450 (CYP450), uma superfamília de enzimas responsável por metabolizar cerca de 75% dos fármacos em uso. Os estudos pré-clínicos de DDI envolvem o conhecimento do potencial inibitório do candidato a fármaco sobre essas enzimas e esses estudos podem ser realizados empregando diversos modelos in vitro, como, por exemplo, microssomas hepáticos de humanos (HLM). Assim, nesse estudo foi avaliado o efeito inibitório da GRA sobre a atividade das principais isoformas do CYP450 e também foram determinadas as isoformas que contribuem para a formação dos metabólitos da GRA. Os resultados demonstraram que múltiplas isoformas participam da formação dos metabólitos da GRA, com destaque para a CYP2C9, que participa da formação de todos os metabólitos. Em relação aos estudos de inibição, foi possível concluir que a GRA é um inibidor fraco da CYP1A2 e CYP2D6, com valores de IC50 maiores do que 200 µM e 100 µM, respectivamente, e um inibidor moderado e competitivo da CYP2C9, com IC50 igual a 40,85 µM e Ki igual a 50,60 µM. Para a CYP3A4 o potencial inibitório da GRA foi avaliado utilizando dois substratos distintos. A GRA demonstrou ser tanto um inibidor dose-dependente moderado e competitivo dessa isoforma, quanto um inibidor tempo-dependente baseado em mecanismo com potencial de inativação equiparável ao do irinotecano, inibidor baseado em mecanismo clinicamente significativo. Utilizando a nifedipina como substrato os valores de IC50 e Ki foram 78,09 µM e 48,71 µM, respectivamente. Já os valores dos parâmetros cinéticos de inativação foram KI= 6,40 µM, kinact= 0,037 min-1 e Clinact= 5,78 mL min-1 µmol-1. Para os ensaios empregando o midazolam os valores de IC50 e Ki foram 48,87 µM e 31,25 µM, respectivamente, e os valores dos parâmetros cinéticos de inativação foram KI= 31,53 µM, kinact= 0,049 min-1 e Clinact= 1,55 mL min-1 µmol-1. Com relação a CYP2E1, por sua vez, foi possível observar que a GRA tem capacidade de aumentar a atividade dessa isoforma significativamente a partir da concentração de 4 µM. Portanto, conclui-se que não há risco da GRA apresentar interações medicamentosas com fármacos metabolizados pela CYP1A2 e CYP2D6, enquanto que para a CYP2C9, apesar da GRA ser um inibidor moderado dessa isoforma, o risco é baixo. Já para medicamentos metabolizados pela CYP2E1 e CYP3A4 o risco de DDI existe e isso deve ser cuidadosamente monitorado in vivo, principalmente porque a CYP3A4 é a isoforma responsável por catalisar o metabolismo da maioria dos fármacos. / (-)-grandisin (GRA) is a lignanic natural product found in many species of plants from North and Northeast of Brazil. This compound has several biological properties, such as trypanocide, anti-inflammatory, antinociceptive, antileukemia activity and antitumor activity against Ehrlich tumor. Because of these biological properties, GRA is considered a potential drug candidate, however, before becoming a new drug, GRA has to undergo various tests, including preclinical drug-drug interactions (DDI) studies. Most of the times, DDI occur because of direct and time-dependent inhibitions of cytochrome P450 (CYP450) enzymes, an enzyme superfamily responsible for metabolizing the vast majority of drugs administered. Preclinical drug-drug interactions studies involve the evaluation of the potential of a drug candidate to inhibit this superfamily of enzymes and these studies can be conducted using in vitro models, such as human liver microsomes (HLM). Therefore, in this project, the inhibitory effect of GRA on the activity of some CYP450 isoforms was evaluated and the isoforms that catalyze the formation of GRA\'s metabolites were also determined. Results showed that multiple CYP450 isoforms participate in the GRA\'s metabolites formation, highlighting CYP2C9, which catalyzes the formation of all metabolites. The inhibition studies showed that GRA is a weak inhibitor of CYP1A2 and CYP2D6, with IC50 values greater than 200 µM and 100 µM, respectively, and a moderate and competitive inhibitor of CYP2C9, with IC50 value equal to 40.85 µM and Ki value equal to 50.60 µM. The capability of GRA to inhibit CYP3A4 was evaluated using two different substrates. GRA showed to be a moderate and competitive dose- dependent inhibitor of this isoform and also a mechanism-based time-dependent inhibitor with potential of inactivation comparable to irinotecan, a clinically significant mechanism-based inhibitor. IC50 and Ki values obtained using nifedipine as substrate were 78.09 µM and 48.71 µM, respectively, and inactivation kinetics parameters were KI= 6.40 µM, kinact= 0,037 min-1 e Clinact= 5.78 mL min-1 µmol-1. On the other hand, IC50 and Ki values using midazolam as substrate were 48.87 µM and 31.25 µM, respectively, and the values of inactivation kinetics parameters were KI= 31.53 µM, kinact= 0,049 min-1 and Clinact= 1.55 mL min-1 µmol-1. With respect to CYP2E1, it was observed that GRA increases its activity significantly from a concentration of 4 µM. Therefore, it is possible to conclude that there is no risk of DDI between GRA and drugs metabolized by CYP1A2 and CYP2D6, while for CYP2C9, although GRA is a moderate inhibitor of this isoform, the risk is low. Finally, for drugs metabolized by CYP3A4 and CYP2E1 there is risk of DDI and this should be carefully monitored in humans, mainly because CYP3A4 is an isoform responsible for catalyzing the metabolism of most drugs in use.

Cytochromes P450 are the major xenobiotics converting enzymes. They are classified as mixed function monooxygenases (MFO). Isoform 1A1 is a extrahepatic form found mainly in the lung and other tissues. It is strongly induced by polycyclic aromatic hydrocarbons and their derivatives via the Ah receptor. As a marker reaction for this enzyme can be used hydroxylation of Sudan I, which has previously been widely used as a azo dye in industry, but since 1980s it is banned for coloring food and cosmetics for its negative influence on the organism. NADPH:cytochrome P450 reductase is the major electron donor for cytochrome P450 catalyzed monooxygenation reactions. Another electron carrier for cytochrome P450 catalyzed reactions is cytochrome b5. It was shown that cytochrome b5 can stimulate, inhibit or have no effect on P450 catalyzed reactions. This thesis aims to evaluate the influence of the ration between NADPH:cytochrome P450 reductase and cytochrome b5 on cytochrome P450 1A1 catalyzed Sudan I hydroxylation. The main goal is to characterize the influence of electron donor and electron transfer ratios on hydroxylation of Sudan I, and to determine the kinetic parameters KM and VMAX for selected protein ratios. Partial aims of the thesis were to characterize the recombinant proteins used in this study...